证券代码：688202 证券简称：美迪西 公告编号：2025-057 上海美迪西生物医药股份有限公司 董事会薪酬与考核委员会 关于公司 2025 年限制性股票激励计划 首次授予激励对象名单的核查意见及公示情况说明 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （二）核查方式 公司董事会薪酬与考核委员会对本激励计划首次授予激励对象的姓名、身份证 件、激励对象与公司、公司分公司或公司控股子公司签署的劳动合同或聘用合同、 激励对象在公司、公司分公司或公司控股子公司担任的职务等情况进行了核查。 二、董事会薪酬与考核委员会核查意见 上海美迪西生物医药股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召 开了第四届董事会第六次会议、第四届监事会第六次会议及第四届董事会薪酬与考 核委员会第二次会议，审议通过了《关于<上海美迪西生物医药股份有限公司 2025 年限制性股票激励计划（草案）>及其摘要的议案》《关于<上海美迪西生物医药 股份有限公司 2025 年限制性股票激励计划实施考核管理办法>的议案》等相关议案， 具体内 ...

Core Viewpoint - Shanghai Medicilon Biomedicine Co., Ltd. plans to terminate certain fundraising projects and redirect the remaining funds to new projects, permanently supplement working capital, and continue to store funds in a special account [1][27]. Group 1: Fundraising and Project Termination - The total amount raised by the company as of August 4, 2023, is RMB 1 billion, with a net amount of RMB 985.29 million after deducting fees [7][10]. - The terminated project is the "North Shanghai Biomedicine R&D Innovation Industrial Base Project," which was intended to enhance drug discovery capabilities but is no longer aligned with market demands [11][12]. - The remaining funds of RMB 289.90 million will be allocated as follows: RMB 40 million for increasing capital in MEDICILON USA CORP, RMB 160 million for working capital, and RMB 89.90 million will remain in the special account [12][13]. Group 2: New Project Overview - The new project involves establishing an "Overseas Marketing and R&D Center" in the U.S. to enhance the company's international presence and service capabilities [13][20]. - The project aims to leverage existing overseas sales and R&D teams to expand the company's market influence and improve customer service efficiency [13][19]. - The company has already established a 2,000 square meter R&D office in Boston, which will serve as a strategic hub for this initiative [20][22]. Group 3: Industry Context and Growth Potential - The global pharmaceutical market is expected to grow steadily, driven by increasing R&D investments, with global R&D spending projected to rise from USD 260.6 billion in 2023 to USD 359.2 billion by 2028, reflecting a CAGR of approximately 6.6% [16][17]. - The CRO (Contract Research Organization) industry is experiencing growth, with increasing demand for outsourced R&D services, which is expected to enhance the market penetration of CROs from 49.2% in 2023 to 58.2% by 2028 [20][21]. - The domestic CRO industry is evolving rapidly, with companies actively seeking to expand internationally and improve their service capabilities to meet global standards [17][22].

证券代码：688202 证券简称：美迪西 上海美迪西生物医药股份有限公司 2025 年第二次临时股东大会会议资料 二〇二五年九月 上海美迪西生物医药股份有限公司 2025 年第二次临时股东大会会议资料目录 | 2025 年第二次临时股东大会会议须知 1 | | --- | | 年第二次临时股东大会会议议程 4 2025 | | 议案一：关于部分募投项目终止并将剩余募集资金投入新项目、永久补充流动资金及继 | | 续存放在募集资金专户的议案 6 | | 议案二：关于取消公司监事会、修订《公司章程》并办理工商变更登记的议案 17 | | 议案三：关于修订和制定公司部分治理制度的议案 67 | | 议案四：关于《上海美迪西生物医药股份有限公司 2025 年限制性股票激励计划（草案）》 | | 及其摘要的议案 68 | | 议案五：关于《上海美迪西生物医药股份有限公司 2025 年限制性股票激励计划实施考 | | 核管理办法》的议案 69 | | 议案六：关于提请股东大会授权董事会办理公司股权激励计划相关事宜的议案 71 | 上海美迪西生物医药股份有限公司 2025 年第二次临时股东大会会议资料 上海美迪西生物医药股 ...

Core Viewpoint - The dispute between Medisi and its client Hongxu Bio over a technology service contract highlights tensions in the GLP-1 drug development sector, with potential implications for Medisi's business reputation and financial stability [1][3][7]. Group 1: Dispute Details - Medisi's subsidiary, Medisi Puya, is being sued by Hongxu Bio for breach of contract related to non-clinical safety evaluation studies for a biopharmaceutical project [1][3]. - The contract required Medisi Puya to complete four experimental projects within eight months and provide reports in both Chinese and English [1]. - Hongxu Bio claims that Medisi Puya failed to fulfill its contractual obligations, seeking contract termination and compensation for losses [1][3]. Group 2: Financial Implications - The lawsuit involves claims exceeding 1 billion yuan, including breach penalties and service fee refunds, which could significantly impact Medisi's financial health [7]. - Medisi reported a total revenue of 540 million yuan in the first half of the year, indicating that a successful lawsuit by Hongxu could lead to substantial financial losses for Medisi [7][9]. - Despite the lawsuit, Medisi's overall business operations remain normal, and the company is actively responding to the legal challenge [7]. Group 3: Company Performance - Medisi's revenue for the first half of the year increased by 3.64% year-on-year to 540 million yuan, with domestic revenue at 292 million yuan and overseas revenue growing by 31.08% to 248 million yuan [9]. - The company reported a net loss of approximately 12.9 million yuan, but this represents a significant reduction in losses compared to the previous year [9]. - Medisi has experienced a decline in revenue and profitability since its peak in 2022, with ongoing challenges in achieving sustainable profitability [8].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688202 证券简称：美迪西 公告编号：2025-056 上海美迪西生物医药股份有限公司 关于参加 2025 年半年度科创板创新药行业集体业绩 说明会的公告 本次投资者说明会以网络文字互动形式召开，公司将针对 2025 年半年度的 经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许 的范围内就投资者普遍关注的问题进行回答。 会议召开时间：2025 年 9 月 16 日（星期二）15:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 二、说明会召开的时间、地点 （一） 会议召开时间：2025 年 9 月 16 日（星期二）15:00-17:00 （二） 会议召开地点：上证路演中心（https://roadshow.sseinfo.com/） （三） 会议召开方式：上证路演中心网络文字 ...

Group 1 - The CRO (Contract Research Organization) concept stocks in the A-share market have shown strong performance, with notable gains in several companies [1] - Zhaoyan New Drug approached the daily limit increase with a rise of 9.12%, while other companies like Kailaiying, Nossger, and Kanglong Chemical also saw increases exceeding 5% [1][2] - The total market capitalization of Zhaoyan New Drug is 25.3 billion, and it has achieved a year-to-date increase of 103.06% [2] Group 2 - Kailaiying's stock rose by 5.48%, with a total market capitalization of 38.7 billion and a year-to-date increase of 42.84% [2] - Nossger and Kanglong Chemical experienced increases of 5.44% and 5.19%, respectively, with market capitalizations of 5.631 billion and 55.5 billion [2] - Other companies such as Sunshine Nuohuo and Boteng also reported gains of over 5%, with year-to-date increases of 109.05% and 64.55% respectively [2]

Core Viewpoint - MediXis (688202.SH) has reported a turnaround in its financial performance for the first half of 2025, with revenue growth and a return to profitability in Q2, indicating a positive shift in the company's trajectory [1][3]. Financial Performance - The company achieved a revenue of 540 million yuan in the first half of 2025, marking a year-on-year increase of 3.64%, ending a previous decline [1]. - The net profit attributable to shareholders was -12.9 million yuan, a significant improvement with an 81.63% reduction in losses compared to the previous year, and a net profit of 1.65 million yuan in Q2, marking the first quarterly profit since 2023 [1][3]. Profitability and Margins - The gross profit margin for the first half of 2025 was 21.24%, a substantial increase of 12.99 percentage points from 8.25% in the same period of 2024, attributed to a higher proportion of high-margin overseas orders [3]. Industry Context - The CRO (Contract Research Organization) industry in China is experiencing a recovery, with a slight increase in orders and stabilization in pricing, as indicated by a total of 368 financing events amounting to 54.7 billion yuan in the first half of 2025 [3]. - The average net profit growth for companies in the CRO sector was 41.39% year-on-year, with several leading firms benefiting from overseas contracts and differentiated technologies [3]. International Expansion and Innovation - MediXis has seen a 40% year-on-year increase in new overseas orders, with revenue from international clients reaching 248 million yuan, a 31.08% increase [3]. - The company has opened two R&D centers in Boston, which are now operational, and has received OECD GLP certification, aligning its quality management systems with international standards [4]. Strategic Initiatives - MediXis plans to implement a restricted stock incentive plan for 2025, targeting a 10% revenue growth or a return to profitability, and aims for a 20% revenue increase or a net profit exceeding 30 million yuan in 2026 [4]. - The company is optimizing its organizational structure by establishing an independent international business division and has appointed a former Pfizer executive to enhance its overseas market capabilities [4]. Future Outlook - Huaxi Securities has raised its revenue forecasts for MediXis for 2025 to 1.144 billion yuan, with subsequent increases projected for 2026 and 2027, reflecting optimism about the company's recovery and growth potential in the domestic market [5].

Group 1 - The first domestically developed pediatric influenza antiviral drug, Maduonosawei granules, has had its market application accepted, targeting the treatment of influenza A and B in children aged 2 to 11 without complications. This marks a significant milestone for the Chinese pharmaceutical industry [1] - The approval of this pediatric drug is expected to provide a new growth point for Xiansheng Pharmaceutical and enhance its competitiveness in the influenza drug market, while also showcasing the innovative drug development capabilities of Antikang Bio [1] Group 2 - Huasheng Technology announced plans to re-list the transfer of a 51% stake in its subsidiary, Tibet Kangyu Pharmaceutical Co., Ltd., with a listing price of 42.5 million yuan. The company has not yet found a suitable buyer after two rounds of bidding, indicating potential market valuation discrepancies [2] - The failure to attract qualified buyers may reflect concerns regarding the future development, competitive landscape, and financial status of Kangyu Pharmaceutical, making the outcome of the re-listing uncertain [2] Group 3 - Lianhuan Pharmaceutical's subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has received domestic approval for its Amlodipine Besylate tablets, a commonly used medication for regulating vascular pressure, with annual sales expected to reach 1.216 billion yuan in 2024 [3] - This approval enhances the product line of the company and its subsidiaries, improving market competitiveness, although the market is already crowded with numerous participants [3] Group 4 - Medisi's wholly-owned subsidiary, Medisi Puya Pharmaceutical Technology (Shanghai) Co., Ltd., has been sued for 159 million yuan due to a technical service contract dispute, with the case already filed but not yet heard [4] - The uncertainty surrounding this lawsuit may increase operational risks for the company and could lead to investor concerns regarding its future development [4] Group 5 - Shanghai Laishi announced that several executives, including the vice chairman and general manager, plan to increase their shareholdings in the company, with a total investment of no less than 6 million yuan sourced from personal funds [5] - Executive share purchases are generally viewed as a positive signal in the capital market, potentially attracting more investor interest and driving up stock prices, although the effectiveness of this plan will depend on market conditions and the company's actual performance [5]

Group 1: Shareholder Equity Change Announcement - The company received a notice from shareholder Lin Changqing regarding a reduction in shareholding, with a total of 950,000 shares sold, representing 0.71% of the total share capital as of September 3, 2025 [1][2] - Following the reduction, Lin Changqing's shareholding decreased from 5,473,654 shares (4.07%) to 4,523,654 shares (3.37%), while the combined holdings of Lin and his associate Chen Guoxing fell from 10,348,808 shares (7.70%) to 9,398,808 shares (7.00%) [1][2] - The reduction in shareholding does not trigger a mandatory tender offer and will not change the company's controlling shareholder or actual controller [2] Group 2: Litigation Involving Subsidiary - The company's wholly-owned subsidiary, MediXipia Pharmaceutical Technology (Shanghai) Co., Ltd., is a defendant in a lawsuit initiated by Hongxu Biological Technology (Beijing) Co., Ltd. regarding a technical service contract dispute [4][5] - The lawsuit, which has been filed but not yet heard, involves a claim amounting to approximately 158.53 million yuan, while the contract amount in question is 5.58 million yuan [5][8] - The company asserts that it has fulfilled its contractual obligations and plans to actively defend against the claims, including potential counterclaims against Hongxu Biological [5][10]

Core Points - The announcement details a change in shareholder equity for Shanghai Medicy Bio-Pharmaceutical Co., Ltd, specifically a reduction in shareholding by major shareholder Lin Changqing [1][2] - Lin Changqing has reduced his shareholding from 5,473,654 shares (4.07%) to 4,523,654 shares (3.37%), resulting in a total reduction of 950,000 shares (0.71%) [1][2] - The combined shareholding of Lin Changqing and his associate Chen Guoxing decreased from 10,348,808 shares (7.70%) to 9,398,808 shares (7.00%) [1][2] Shareholder Information - Lin Changqing is the primary shareholder involved in the equity change, while Chen Guoxing remains unchanged with 487,515.4 shares (3.63%) [2] - The equity change does not trigger mandatory tender offer obligations and will not affect the company's controlling shareholder or actual controller [2] Additional Notes - The equity change is part of a previously disclosed share reduction plan, which is still in progress as of the announcement date [2] - The company will continue to comply with relevant regulations and fulfill its information disclosure obligations [2][3]